LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 13 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 3. - Dataset (ID:20250)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Seliciclib | 10 | uM | LJP5 | 72 | hr | 1097 | 1639 | 3846 | 0.4263 | 0.2482 |
BT-20 | AT-7519 | 0.04 | uM | LJP6 | 72 | hr | 1097 | 3026 | 3673 | 0.8238 | 0.7896 |
BT-20 | AT-7519 | 0.12 | uM | LJP6 | 72 | hr | 1097 | 1875 | 3673 | 0.5105 | 0.3589 |
BT-20 | AT-7519 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 832 | 3673 | 0.2262 | -0.1485 |
BT-20 | AT-7519 | 1.11 | uM | LJP6 | 72 | hr | 1097 | 588 | 3673 | 0.1600 | -0.3020 |
BT-20 | AT-7519 | 3.33 | uM | LJP6 | 72 | hr | 1097 | 540 | 3673 | 0.1468 | -0.3382 |
BT-20 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1097 | 529 | 3673 | 0.1442 | -0.3420 |
BT-20 | AZD7762 | 0.04 | uM | LJP6 | 72 | hr | 1097 | 3676 | 3673 | 1.0006 | 1.0000 |
BT-20 | AZD7762 | 0.12 | uM | LJP6 | 72 | hr | 1097 | 2846 | 3673 | 0.7742 | 0.7255 |
BT-20 | AZD7762 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 2115 | 3673 | 0.5756 | 0.4564 |
BT-20 | AZD7762 | 1.11 | uM | LJP6 | 72 | hr | 1097 | 1307 | 3673 | 0.3559 | 0.1055 |
BT-20 | AZD7762 | 3.33 | uM | LJP6 | 72 | hr | 1097 | 750 | 3673 | 0.2042 | -0.1962 |
BT-20 | AZD7762 | 10 | uM | LJP6 | 72 | hr | 1097 | 456 | 3673 | 0.1241 | -0.3966 |
BT-20 | AZD8055 | 0.04 | uM | LJP6 | 72 | hr | 1097 | 1423 | 3673 | 0.3873 | 0.1601 |
BT-20 | AZD8055 | 0.12 | uM | LJP6 | 72 | hr | 1097 | 1170 | 3673 | 0.3188 | 0.0367 |
BT-20 | AZD8055 | 0.37 | uM | LJP6 | 72 | hr | 1097 | 1116 | 3673 | 0.3039 | 0.0097 |
BT-20 | AZD8055 | 1.11 | uM | LJP6 | 72 | hr | 1097 | 1050 | 3673 | 0.2858 | -0.0251 |
BT-20 | AZD8055 | 3.33 | uM | LJP6 | 72 | hr | 1097 | 906 | 3673 | 0.2468 | -0.1038 |
BT-20 | AZD8055 | 10 | uM | LJP6 | 72 | hr | 1097 | 119 | 3673 | 0.0326 | -0.7198 |
BT-20 | Sorafenib | 0.04 | uM | LJP6 | 72 | hr | 1097 | 3411 | 3673 | 0.9288 | 0.9170 |
BT-20 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 1097 | 3487 | 3673 | 0.9497 | 0.9413 |
BT-20 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 1097 | 3050 | 3673 | 0.8306 | 0.7963 |
BT-20 | Sorafenib | 1.11 | uM | LJP6 | 72 | hr | 1097 | 3091 | 3673 | 0.8415 | 0.8115 |
BT-20 | Sorafenib | 3.33 | uM | LJP6 | 72 | hr | 1097 | 3110 | 3673 | 0.8471 | 0.8185 |
BT-20 | Sorafenib | 10 | uM | LJP6 | 72 | hr | 1097 | 1328 | 3673 | 0.3613 | 0.1140 |